Join
Live feed
·
INSIDERFilingvia Quantisnow
Inhibikase Therapeutics Inc. logo

Director Kush Arvind bought $198,650 worth of shares (145,000 units at $1.37) (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IKT (Inhibikase Therapeutics Inc.) and more on Quantisnow.